PubRank

Targeted oncology (Target Oncol)

Journal PubWeight™ 236.90‹?›

Top papers

Rank Title Year PubWeight™‹?›
1 Skin toxicities associated with epidermal growth factor receptor inhibitors. 2009 2.06
2 Regorafenib: start low and go slow. 2014 1.95
3 EGFR inhibitors in non-small cell lung cancer (NSCLC): the emerging role of the dual irreversible EGFR/HER2 inhibitor BIBW 2992. 2010 1.58
4 Treatment selection after imatinib resistance in chronic myeloid leukemia. 2009 1.36
5 Presently available biosimilars in hematology-oncology: G-CSF. 2012 1.34
6 Common toxicities of mammalian target of rapamycin inhibitors. 2011 1.34
7 The economic pressures for biosimilar drug use in cancer medicine. 2012 1.34
8 Uptake of KRAS mutation testing in patients with metastatic colorectal cancer in Europe, Latin America and Asia. 2011 1.32
9 Pulmonary toxicities from targeted therapies: a review. 2011 1.28
10 Mechanisms of mTOR inhibitor resistance in cancer therapy. 2011 1.27
11 Role of targeted agents in metastatic colorectal cancer. 2013 1.22
12 The emerging safety profile of mTOR inhibitors, a novel class of anticancer agents. 2009 1.21
13 Dynamic contrast-enhanced ultrasonography (DCE-US): a new tool for the early evaluation of antiangiogenic treatment. 2010 1.21
14 Complete remission of unresectable hepatocellular carcinoma treated with reduced dose of sorafenib: a case report. 2010 1.19
15 Posterior reversible encephalopathy syndrome induced by anti-VEGF agents. 2011 1.17
16 Axitinib--a selective inhibitor of the vascular endothelial growth factor (VEGF) receptor. 2009 1.15
17 Epidermal growth factor receptor (EGFR) mutation and personalized therapy in advanced nonsmall cell lung cancer (NSCLC). 2013 1.13
18 Designs and challenges for personalized medicine studies in oncology: focus on the SHIVA trial. 2012 1.13
19 The predictive role of skin rash with cetuximab and panitumumab in colorectal cancer patients: a systematic review and meta-analysis of published trials. 2013 1.12
20 Targeting integrins in malignant glioma. 2010 1.11
21 Targeting regulatory T cells. 2012 1.10
22 The potential of optical proteomic technologies to individualize prognosis and guide rational treatment for cancer patients. 2009 1.10
23 Comment on: "Regorafenib: Start Low and Go Slow". 2016 1.08
24 Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitors. 2009 1.08
25 Hyperbaric oxygen therapy and cancer--a review. 2012 1.07
26 Cardiovascular toxicities: clues to optimal administration of vascular endothelial growth factor signaling pathway inhibitors. 2009 1.07
27 Biosimilars and market access: a question of comparability and costs? 2012 1.07
28 Diffusion-weighted (DW) and dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) for monitoring anticancer therapy. 2010 1.03
29 Targeted therapies for non-clear renal cell carcinoma. 2010 1.02
30 ALK inhibitors: a new targeted therapy in the treatment of advanced NSCLC. 2013 1.02
31 Non-Small-Cell Lung Cancer (NSCLC) Harboring ALK Translocations: Clinical Characteristics and Management in a Real-Life Setting: a French Retrospective Analysis (GFPC 02-14 Study). 2017 1.02
32 Targeting mTOR in cancer: renal cell is just a beginning. 2010 1.01
33 Targeting insulin-like growth factor type 1 receptor in cancer therapy. 2009 1.00
34 Targeting mitogen-activated protein kinase kinase (MEK) in solid tumors. 2009 0.99
35 Cardiac toxicity with anti-HER-2 therapies: what have we learned so far? 2009 0.98
36 A review on various targeted anticancer therapies. 2012 0.98
37 Interleukin-7 and immune reconstitution in cancer patients: a new paradigm for dramatically increasing overall survival. 2012 0.98
38 Mammalian target of rapamycin expression in poorly differentiated endocrine carcinoma: clinical and therapeutic future challenges. 2011 0.97
39 MGMT promoter methylation in malignant gliomas. 2010 0.97
40 Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trial. 2014 0.96
41 Targeting phosphatidylinositol 3 kinase (PI3K)-Akt beyond rapalogs. 2011 0.96
42 The emerging role of mammalian target of rapamycin inhibitors in the treatment of sarcomas. 2011 0.95
43 The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients. 2013 0.95
44 Immune therapeutic targeting of glioma cancer stem cells. 2010 0.95
45 Antisense inhibition of microRNA-21 and microRNA-221 in tumor-initiating stem-like cells modulates tumorigenesis, metastasis, and chemotherapy resistance in pancreatic cancer. 2015 0.93
46 Microsatellite instability: a predictive marker in metastatic colorectal cancer? 2009 0.93
47 Optical tomography of breast cancer-monitoring response to primary medical therapy. 2009 0.92
48 Ultrasound-guided direct delivery of 3-bromopyruvate blocks tumor progression in an orthotopic mouse model of human pancreatic cancer. 2013 0.92
49 Tyrosine kinase inhibitor-induced hypothyroidism: incidence, etiology, and management. 2011 0.92
50 Heterogeneity of the EGFR mutation status between the primary tumor and metastatic lymph node and the sensitivity to EGFR tyrosine kinase inhibitor in non-small cell lung cancer. 2012 0.92
Next 50